Zhou X, Dierks A, Kertels O, Samnick S, Kircher M, Buck AK, Haertle L, Knorz S, Boeckle D, Scheller L, Messerschmidt J, Barakat M, Truger M, Haferlach C, Einsele H, Rasche L, Kortuem KM, Lapa C (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 12
Pages Range: 1-13
Article Number: 2399
Journal Issue: 9
Utilizing 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT), we performed this pilot study to evaluate the link between cytogenetic/genomic markers and imaging patterns in relapsed/refractory (RR) multiple myeloma (MM). We retrospectively analyzed data of 24 patients with RRMM who were treated at our institution between November 2018 and February 2020. At the last relapse/progression, patients had been treated with a median of three (range 1–10) lines of therapy. Six (25%) patients showed FDG avid extramedullary disease without adjacency to bone. We observed significantly higher maximum standardized uptake values (SUV
APA:
Zhou, X., Dierks, A., Kertels, O., Samnick, S., Kircher, M., Buck, A.K.,... Lapa, C. (2020). The link between cytogenetics/genomics and imaging patterns of relapse and progression in patients with relapsed/refractory multiple myeloma: A pilot study utilizing 18f-fdg pet/ct. Cancers, 12(9), 1-13. https://doi.org/10.3390/cancers12092399
MLA:
Zhou, Xiang, et al. "The link between cytogenetics/genomics and imaging patterns of relapse and progression in patients with relapsed/refractory multiple myeloma: A pilot study utilizing 18f-fdg pet/ct." Cancers 12.9 (2020): 1-13.
BibTeX: Download